Christopher S Reeves

US Patent:

20130178652, Jul 11, 2013

Filed:

Mar 1, 2013

Appl. No.:

13/781834

Inventors:

Arkema Inc. - King of Prussia PA, US
Christopher T. Reeves - Durham NC, US
William C. Brooks - Saint Albans WV, US
Edmund J. Yang - Houston TX, US
Roger L. Roundy - Rosharon TX, US

Assignee:

Arkema Inc. - King of Prussia PA

International Classification:

C07C 51/38

US Classification:

562598

Abstract:

The method of inhibiting the polymerization of a mono-ethylenically unsaturated carboxylic acid, anhydride, ester or neutralized or partially neutralized salt, e.g., an acrylic acid or ester, in an aqueous solution and in the presence of oxygen, the method comprising the step of mixing with the aqueous solution an inhibitor comprising (i) at least 50 ppm of an N-oxyl compound, e.g., 4-hydroxy-TEMPO, and (ii) a manganese ion, the N-oxyl compound and manganese ion present in a N-oxyl compound to manganese ion weight ratio of 50:1 to less than 100:1. based on the mono-ethylenically unsaturated carboxylic acid, anhydride, ester or salt.

US Patent:

52504352, Oct 5, 1993

Filed:

Jun 4, 1991

Appl. No.:

7/709950

Inventors:

William H. Cover - Lansdale PA
Rebecca L. Dabora - Andover MA
Anderson Hong - Taipei, TW
Christopher Reeves - Mill Creek WA
Robert W. Stieber - Harrisonburg VA
Victor A. Vinci - Charlottesville VA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12P 742
C12P 1706
C12N 114
C07D30500

US Classification:

4352561

Abstract:

Novel strains of Aspergillus terreus have been discovered which provide fermentation production of at least 5. 2 g/L of 7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naphthyl ]-3(R),5(R)-dihydroxyheptanoic acid (triol acid, I), but with production of not more than 0. 85 g/L of (triol acid)-related side products and specifically less than 0. 10 mg/liter of lovastatin. The predominant fermentation product triol acid, may be converted in a straightforward manner to its lactone form, in which it is an inhibitor of HMG-CoA reductase and thus useful as an antihypercholesterolemic agent, and in which it may also serve as an intermediate for preparation of other HMG-CoA reductase inhibitors.